Yucheng Lu | Neuroscience | Research Excellence Award

Prof. Yucheng Lu | Neuroscience | Research Excellence Award

Linyi People's Hospital | China

Prof. Yucheng Lu is a distinguished researcher whose scholarly contributions span cancer biology, immunology, and translational biomedical sciences. With 352 citations, 26 indexed publications, and an h-index of 13, he has established a strong research footprint in molecular oncology and disease pathology. Over his academic career, he has published 40 peer-reviewed papers, including 25 as first or corresponding author, reflecting consistent leadership in scientific inquiry. His work encompasses cutting-edge topics such as tumor-associated macrophage regulation in glioma, prognostic biomarkers in low-grade glioma, colorectal cancer therapeutics, and single-cell transcriptomics in esophageal cancer. In addition, he has explored metabolic and immunological disease interactions, cancer proliferation mechanisms, and neural electrophysiological responses. As a principal investigator, he has led 7 provincial and municipal research projects and contributed to 8 national and ministerial-level initiatives, demonstrating strong project management and interdisciplinary collaboration. His research excellence has earned 3 Science and Technology Achievement Awards, alongside innovations represented by 1 invention patent and 6 software copyrights. Through these achievements, Prof. Lu continues to advance biomedical research with significant scientific, clinical, and technological impact.

Profile : Scopus | Orcid

Featured Publications

Shi, H., Cheng, Y., Chao, D., Song, Q., Han, L., Li, H., Lu, Y., & Wang, M. (2025). Spatiotemporal profiling of endocytic regulators in the immunosuppressive TAM microenvironment of glioma. Brain Research, 150086. (In press)

Author names not provided. (2025). Identification of CDKN3 overexpression as a marker of poor prognosis and potential therapeutic target in low-grade glioma. Scientific Reports.

Author names not provided. (2025). Okanin suppresses the growth of colorectal cancer cells by targeting Peroxiredoxin 5. Advanced Science.

Shi, K., Li, Y., Yang, L., Zhang, Z., Guo, D., Zhang, J., & Lu, Y. (2022). Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing. The FASEB Journal, 0892-6638.

Zhao, J. Z., Lu, Y. C., Wang, Y. M., Xiao, B. L., Li, H. Y., Lee, S. C., & Wang, L. J. (2022). Association between diabetes and acute lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma. International Journal of Diabetes in Developing Countries, 0973-3930.

Shi, K., Zhang, J. Z., Yang, L., Li, N. N., Yue, Y., Du, X. H., Zhang, X. Z., Lu, Y. C., & Guo, D. (2021). Protein deubiquitylase USP3 stabilizes Aurora A to promote proliferation and metastasis of esophageal squamous cell carcinoma. BMC Cancer, 1471-2407.

Lu, Y., Lv, B., & Song, Q. (2019). Transcranial electrical stimulation motor-evoked potentials in a spinal cord ischaemia rabbit model. Chinese Neurosurgical Journal, 2057-4967.

Lu, Y. C., Wang, P., Wang, J., Ma, R., & Lee, S. C. (2019). PCNA and JNK1-Stat3 pathways respectively promote and inhibit diabetes-associated centrosome amplification by targeting the ROCK1/14-3-3σ complex in human colon cancer HCT116 cells. Journal of Cellular Physiology.

Jeong A Kim | Medicine and Dentistry | Best Researcher Award

Prof. Jeong A Kim | Medicine and Dentistry | Best Researcher Award

St. Vincent Hospital, The Catholic University of Korea | South Korea

Author Profile

Scopus

Early Academic Pursuits ✨

Prof. Jeong A Kim embarked on an illustrious academic journey in the field of medicine, laying a solid foundation at the Catholic University Medical College. She completed her premedical course in 1986, followed by earning her Doctor of Medicine degree in 1990. Her passion for internal medicine and hematology led her to pursue advanced studies at The Catholic University of Korea, where she obtained a Master’s degree in 1998 and a Ph.D. in 2001. This strong academic background established her as a dedicated scholar committed to the advancement of medical sciences.

Professional Endeavors 🏥

Prof. Kim's professional career began with rigorous postdoctoral training. She completed her internship at St. Mary’s Hospital in 1991, followed by a residency in Internal Medicine at Catholic University Medical College until 1995. She further honed her expertise in hemato-oncology through a fellowship at Samsung Medical Center. Her international exposure expanded when she joined the Department of Microbiology and Immunology at IUPUI, USA, as a postdoctoral researcher. Her academic appointments at The Catholic University of Korea saw a steady rise, from Instructor in 1997 to Assistant Professor in 2001, Associate Professor in 2009, and finally attaining the prestigious title of Professor of Internal Medicine in 2014. In parallel, she has been a dedicated physician at St. Vincent Hospital since 1997 and has been leading the hematology and stem cell transplantation center since 2018.

Contributions and Research Focus 📝

Prof. Kim has made groundbreaking contributions in hematology and oncology, with a primary focus on stem cell transplantation, multiple myeloma, and lymphoma. Her extensive clinical trials and research studies have played a pivotal role in developing new treatment modalities for hematologic malignancies. Her work in targeted therapies, chemotherapy combinations, and immunotherapy has significantly improved patient outcomes and quality of life. She has been involved in more than 60 clinical trials, evaluating novel drug efficacy and safety, including studies on Zoledronic acid for multiple myeloma, targeted treatments like Dasatinib for leukemia, and the role of rituximab in lymphoma. Her research has also delved into prognostic factors, precision medicine, and innovative therapeutic strategies for refractory and relapsed hematologic diseases.

Accolades and Recognition 🏆

Prof. Kim's relentless pursuit of excellence has earned her recognition from esteemed medical institutions and societies. As a member of the Korean Association of Internal Medicine, the Korean Hematology Association, and the American Hematology Association, she has played an instrumental role in shaping global hematologic research. Her contributions have been acknowledged through numerous awards, invitations as a keynote speaker, and influential publications in high-impact medical journals.

Impact and Influence ✨

With a career spanning decades, Prof. Kim has mentored numerous young medical professionals, guiding them in clinical research and evidence-based medical practice. Her work has directly influenced hematologic treatment protocols in Korea and internationally. Her leadership in hematology and stem cell transplantation has set new benchmarks in patient care and innovative treatment approaches.

Legacy and Future Contributions 🌟

Prof. Jeong A Kim's legacy is deeply ingrained in the advancements of hematology and oncology. Her dedication to research, patient care, and education continues to inspire the next generation of medical professionals. Looking ahead, she remains committed to pioneering more targeted therapies, enhancing stem cell transplantation techniques, and improving long-term survival rates for hematologic malignancy patients. With ongoing research and collaborations, she is poised to make even greater strides in the field, leaving an indelible mark on medical science and patient care.

 

Publications


📄 The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma
Authors: H. Cho, J. Kim, Y. Park, Y. Kim, J. Kim, Jeong-ah
Journal: Leukemia Research
Year: 2025


📄 Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Authors: N.L. Bartlett, U.H. Hahn, W. Kim, F. Jie, J. Kim, Jeong-ah
Journal: Journal of Clinical Oncology
Year: 2025


📄 Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
Authors: D. Shin, S. Park, E. Jang, W. Lee, D. Kim
Journal: Leukemia Research
Year: 2024


📄 Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Authors: H.Y. Yhim, Y. Park, J. Kim, Jeong-ah, D. Yang, J. Kwak
Journal: The Korean Journal of Internal Medicine
Year: 2024